General
Preferred name
CARISOPRODOL
Synonyms
Carisoprodol civ ()
Rela ()
Carisoma ()
Soma ()
NSC-172124 ()
Carisoprodol-d7 (propyl-d7) ()
Carisoprodol-d7 (propyl-d7) (CRM) ()
P&D ID
PD002442
CAS
78-44-4
1218911-70-6
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1959
Drug Status
approved
withdrawn
Drug indication
Musculoskeletal disorder
Relaxant (skeletal muscle)
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Carisoprodol is a racemic mixture of enantiomers; R-carisoprodol and S-carisoprodol. We show the non-stereo molecule to represent the mixture. (GtoPdb)
INDICATION Carisoprodol is indicated for the relief of discomfort related to acute, painful musculoskeletal conditions [FDA label].; ; ; **Important limitations of use** [FDA label]:; ; • Should only be used for acute treatment periods up to two or three weeks ; ; • Adequate evidence of effectiveness for more prolonged use has not been established ; ; • Not recommended in pediatric patients less than 16 years of age
MOA The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been confirmed.; In studies using animal models, the muscle relaxation that is induced by carisoprodol is associated with a change in the interneuronal activity of the spinal cord and of the descending reticular formation, located in the brain [FDA label]. ; ; The abuse potential of this drug is attributed to its ability to alter GABAA function [A176077]. This drug has been shown to modulate a variety of GABAA receptor subunits [A176062, A176086]. GABAA receptor modulation can lead to anxiolysis due to inhibitory effects on neurotransmission [A173848].
ABSORPTION The absolute bioavailability of carisoprodol has not yet been established. The mean time to peak plasma concentrations (Tmax) of this drug was about 1.5-2 hours in clinical studies [FDA label]. Co-administration of a fatty meal with carisoprodol (350 mg tablet) had no impact on carisoprodol pharmacokinetics [FDA label].
HALF-LIFE The terminal half-life is approximately 2 hours [FDA label].
METABOLISM The main pathway of carisoprodol is liver metabolism is by the cytochrome enzyme CYP2C19 to form meprobamate. This enzyme exhibits genetic polymorphism, which may affect the metabolism of this drug [FDA label].
ROE Carisoprodol is eliminated by the kidneys as well as other routes. The half-life of meprobamate is approximately 10 hours [FDA label].
INDICATION Carisoprodol is indicated for the relief of discomfort related to acute, painful musculoskeletal conditions [FDA label]. **Important limitations of use** [FDA label]: • Should only be used for acute treatment periods up to two or three weeks • Adequate evidence of effectiveness for more prolonged use has not been established • Not recommended in pediatric patients less than 16 years of age
MOA The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been confirmed. In studies using animal models, the muscle relaxation that is induced by carisoprodol is associated with a change in the interneuronal activity of the spinal cord and of the descending reticular formation, located in the brain [FDA label]. The abuse potential of this drug is attributed to its ability to alter GABAA function [A176077]. This drug has been shown to modulate a variety of GABAA receptor subunits [A176062, A176086]. GABAA receptor modulation can lead to anxiolysis due to inhibitory effects on neurotransmission [A173848].
PHARMACODYNAMICS Carisoprodol is a centrally acting skeletal muscle relaxant that does not act directly on skeletal muscle but acts directly on the central nervous system (CNS). This drug relieves the painful effects of muscle spasm [A176101, F4093]. A metabolite of carisoprodol, _meprobamate_, possesses both anxiolytic and sedative properties [FDA label]. Clinical studies have shown that this drug causes impairment of psychomotor performance in neuropsychological tests [A176062, A176095].
DESCRIPTION Skeletal muscle relaxant (LOPAC library)
Cell lines
1
Organisms
0
Compound Sets
21
Cayman Chemical Bioactives
30778
19103
30942
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1233
ChEMBL Drugs
CHEMBL1233
DrugBank
DB00395
DrugBank Approved Drugs
DB00395
DrugCentral
509
DrugCentral Approved Drugs
509
DrugMAP
DMWR1JC
DrugMAP Approved Drugs
DMWR1JC
DrugMatrix
Guide to Pharmacology
7610
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1233
NCATS Inxight Approved Drugs
21925K482H
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
Withdrawn 2.0
w209
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
260.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
0
Aromatic Ring Count
0
cLogP
2.02
TPSA
90.65
Fraction CSP3
0.83
Chiral centers
1.0
Largest ring
0.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Skeletal muscle
MOA
ionotropic GABA receptor agonist
ATC
M03BA02
M03BA52
M03BA72
Toxicity type
multiple
Source data